Astellas ( Astellas)

Primary tabs

Astellas's picture

Management

Contact Address

About Astellas

Astellas Pharma US, Inc., is the U.S. affiliate of Astellas Pharma Inc., a R&D-driven global pharmaceutical company. At Astellas, we improve lives through innovative and effective medicines. Our dedication to changing tomorrow for patients and our customers fits closely with our strong scientific orientation and focus on the community in which we work and live.

Astellas press release, blog etc

Sat, 06/14/2025 - 11:34 Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Fri, 05/30/2025 - 00:16 Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
Wed, 05/28/2025 - 12:19 Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week To Empower Patients and Caregivers
Wed, 05/21/2025 - 11:16 Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
Thu, 03/06/2025 - 00:20 Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
Thu, 02/27/2025 - 11:31 Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
Wed, 02/05/2025 - 11:15 Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
Sat, 01/11/2025 - 01:18 U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
Thu, 12/19/2024 - 21:29 Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Thu, 11/21/2024 - 11:11 Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA for Heart Failure Management
Sun, 09/08/2024 - 20:39 Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
Tue, 08/27/2024 - 14:45 Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
Mon, 07/22/2024 - 10:45 Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
Thu, 06/20/2024 - 13:49 Astellas Announces Sponsored Research Agreement with UMass Chan Medical School
Tue, 06/11/2024 - 17:28 Astellas Coordinates Patient Advocacy Organization (PAO) Action Week to Connect Patients with Critical Resources
Thu, 05/23/2024 - 00:59 Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
Wed, 05/08/2024 - 22:18 Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
Wed, 05/01/2024 - 20:21 Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
more

InfoBox

HomePagewww.astellas.us
Twittertwitter.com/astellasus
LinkedInwww.linkedin.com/company/astellas-pharma
Wikipediaen.wikipedia.org/wiki/Astellas_Pharma